| Sep 2 |
ALNY Down Despite Positive Data From Heart Disease Drug Study
|
| Sep 2 |
Alnylam Pharmaceuticals Insiders Sold US$5.0m Of Shares Suggesting Hesitancy
|
| Aug 30 |
Why IBD 50's Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged
|
| Aug 30 |
Market Whales and Their Recent Bets on ALNY Options
|
| Aug 30 |
Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug
|
| Aug 30 |
ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam
|
| Aug 30 |
Alnylam tumbles, BridgeBio gains after heart drug data
|
| Aug 30 |
Alnylam: HELIOS-B Success Priced In Already
|
| Aug 30 |
Alnylam Pharmaceuticals Reports Substantial Results of Vutrisiran's Phase 3 Study as Heart Disease Therapy
|
| Aug 30 |
Alnylam falls after full data for heart drug that can rival Pfizer’s
|
